The Role of Serotonin in Posttraumatic Stress Disorder: Neurobiology and Pharmacotherapy

CNS Spectrums

Volumn 3, Issue S2, 1998, Pages 42-51

  Connor, Kathryn M ^a   Davidson, Jonathan R t ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011531673     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900007318     Document Type: Article

References (43)

1. Resnick, PJ. Guidelines for the evaluation of malingering in posttraumatic stress disorder. In: Simon, RL, ed. Posttraumatic Stress Disorders in Litigation. Washington, DC: American Psychiatric Association Press; 1995: 117–136.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association Press; 1980.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association Press; 1994.
4. Solomon, SD, Davidson, JRT. Trauma, prevalence, impairment, service use, and cost. J Clin Psychiatry. 1997; 58(suppl 9):5–11.
5. Bresalu, N, Davis, GC, Andreski, P, et al. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 1991; 48: 216–222.
6. Robin, RW, Chester, B, Rasmussen, JK, et al. Prevalence and characteristics of trauma and posttraumatic stress disorder in a southwestern American Indian community. Am J Psychiatry. 1997; 154: 1582–1588.
7. McFarlane, AC. The aetiology of posttraumatic morbidity: predisposing, precipitating, and perpetuating factors. Br J Psychiatry. 1989; 154: 221–228.
8. Kessler, R, Sonnega, A, Bromet, E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995; 52: 1048–1060.
9. Breslau, N, Davis, GC, Andreski, P, et al. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 1991; 48: 216–222.
10. Blank, AS. The longitudinal course of posttraumatic stress disorder. In: Davidson, JRT, Foa, EB, eds. Posttraumatic Stress Disorder: DSM-IV and Beyond. Washington, DC: American Psychiatric Association Press; 1993: 3–12.
11. Rothbaum, BO, Foa, EB. Symptoms of posttraumatic stress disorder and duration of symptoms. In: Davidson, JRT, Foa, EB, eds. Posttraumatic Stress Disorder: DSM-IV and Beyond. Washington, DC: American Psychiatric Association Press; 1993: 23–26.
12. Rothbaum, BO, Foa, EB, Riggs, DS, et al. A prospective examination of post-traumatic stress disorder in rape victims. J Trauma Stress. 1992; 5: 455–475.
13. Koss, MP, Woodruff, WJ, Koss, PG. Criminal victimization among primary care medical patients: prevalence, incidence, and physician usage. Behavioral Science and Law. 1990; 9: 85–96.
14. Kimerling, R, Calhoun, KS. Somatic symptoms, social support, and treatment among sexual assault victims. J Consult Clin Psychol. 1994; 62: 333–340.
15. Weissman, A, Herbert, CA. Recent developments relating serotonin and behavior. Annual Reports of Medicinal Chemistry. 1972; 7: 47–58.
16. Hensman, R, Guimaraes, FS, Wang, M, Deakin, JFW. Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology. 1991; 104: 220–224.
17. Deakin, JFW. 5HT2 receptors, depression, and anxiety. Pharmacol Biochem Behav. 1988; 29: 819–826.
18. Joseph, MH, Kennell, GA. Corticosteroid response to stress depends upon increased tryptophan availability. Psychopharmacology. 1983; 79: 79–81.
19. Kennett, GA, Dickinson, SL, Curzon, G. Enhancement of some 5-HT-dependent behavioural responses following repeated immobilization in rats. Brain Res. 1985; 330: 253–23.
20. Petty, F, Kramer, GL, Wu, J. Serotonergic modulation of learned helplessness. In: Yehuda, R, McFarlane, AC, eds. Psychobiology of Posttraumatic Stress Disorder. New York, NY: The New York Academy of Sciences; 1997: 538–541.
21. Arora, RC, Fichtner, CG, O'Connor, F, Crayton, JW. Paroxetine binding in the blood platelets of posttraumatic stress disorder patients. Life Sci. 1993; 53: 919–928.
22. Fichtner, CG, Arora, RC, O'Connor, FL, Crayton, JW. Platelet paroxetine binding and fluoxetine pharma-cotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sci. 1994; 54: 39–44.
23. Southwick, SM, Yehuda, R, Morgan, CA III., Clinical studies of neurotransmitter alterations in post-traumatic stress disorder. In: Friedman, MJ, Charney, DS, Deutsch, AY, eds. Neurobiology and Clinical Consequences of Stress: From Normal Adaptation to PTSD. New York, NY: Lippincott-Raven; 1995: 335–349.
24. Shuff, N, Marmar, CR, Weiss, DS, et al. Reduced hippocampal volume and N-acetyl aspartate in posttraumatic stress disorder. In: Yehuda, R, McFarlane, AC, eds. Psychobiology of Posttraumatic Stress Disorder. New York, NY: The New York Academy of Sciences: 1997: 516–520.
25. McDougle, CJ, Southwick, SM, Charney, DS, St. James, RL. An open clinical trial of fluoxetine in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol. 1991; 11: 325–327.
26. Shay, J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat veterans with PTSD. J Trauma Stress. 1992; 5: 97–101.
27. Nagy, LM, Morgan, CA, Southwick, SM, Charney, DS. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol. 1993; 13: 107–114.
28. Davidson, J, Roth, S, Newman, E. Fluoxetine in post-traumatic stress disorder. J Trauma Stress. 1991; 4: 419–423.
29. De Boer, M, Op den Velde, W, Falger, RJR, et al. Fluvoxamine treatment for chronic PTSD. Psychother Psychosom. 1991; 57: 158–163.
30. Marmar, CR, Schoenfeld, F, Weiss, DS, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996; 14: 79–81.
31. Rothbaum, BO, Ninan, PT, Thomas, L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress. 1996; 9: 865–871.
32. Kline, NA, Dow, BM, Brown, SA, Matloff, JA. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1994; 151: 621.
33. Davidson, JRT, Weisler, RH, Malik, ML, Connor, MK. Treatment of posttraumatic stress disorder with nefazodone. Int Clin Psychopharmacol. 1998. In press.
34. Fichtner, CG, Crayton, JW. Buspirone in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1994; 57(suppl 8):66–72.
35. Hertzberg, MA, Feldman, ME, Beckham, JC, Davidson, JRT. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996; 16: 294–298.
36. Brophy, MH. Cyproheptadine for combat nightmares in posttraumatic stress disorder and dream anxiety disorder. Mil Med. 1991; 156: 100–101.
37. Van der Kolk, BA, Dreyfuss, D, Michaels, M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994; 55: 517–522.
38. Davidson, JRT, Kudler, H, Smith, R, et al. Treatment of post-traumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990; 47: 259–266.
39. Davidson, JRT, Kudler, HS, Saunders, WB, et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993; 150: 1024–1029.
40. Kosten, TR, Frank, JB, Dan, E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991; 1179: 366–70.
41. Katz, RJ, Lott, MH, Arbus, P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety. 1995; 1: 169–174.
42. Baker, DG, Diamond, BI, Gillette, G, et al. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacobgy. 1995; 122: 386–389.
43. Connor, KM, Davidson, JRT, Tupler, LA, et al. Pharmacotherapy for Civilians with Posttraumatic Stress Disorder: Differential Response Patterns of Fluoxetine and Placebo. Presented at the National Institute of Mental Health New Clinical Drug Evaluation Unit Meeting. Boca Raton, Florida. June, 1998.